^Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ (2015). „The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiatorN-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)”.J. Med. Chem.58 (10): 4291—308.PMID25905800.doi:10.1021/acs.jmedchem.5b00300.
^абвгдђRanganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D'Souza DC (2017). „Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242”.Mol. Psychiatry.22 (11): 1633—1640.PMID28242871.S2CID3691566.doi:10.1038/mp.2017.6.
^Bednar MM, DeMartinis N, Banerjee A, Bowditch S, Gaudreault F, Zumpano L, Lin FR (2015). „The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A Randomized Clinical Trial”.JAMA Otolaryngol Head Neck Surg.141 (7): 607—13.PMID25997115.doi:10.1001/jamaoto.2015.0791.
^Froestl W, Muhs A, Pfeifer A (2012). „Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors”.J. Alzheimers Dis.32 (4): 793—887.PMID22886028.doi:10.3233/JAD-2012-121186.
^абSinger P, Dubroqua S, Yee BK (2015). „Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?”.Curr. Pharm. Des.21 (26): 3771—87.PMID26205290.doi:10.2174/1381612821666150724100952.
.PMID 25243609.doi:10.1517/13543784.2015.960076. 
Podaci na Vikipodacima